Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.

A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.

Mattias Ivarsson, co-founder and CEO of Swiss biotech company Inositec, talks to Lucie Ellis, senior writer at Scrip, about the company's technology and progress since being founded in 2015.